MUFG Americas Holdings Corp Sells 7,149 Shares of Zoetis Inc. (ZTS)
MUFG Americas Holdings Corp trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 25.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,078 shares of the company’s stock after selling 7,149 shares during the quarter. MUFG Americas Holdings Corp’s holdings in Zoetis were worth $1,344,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in ZTS. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after acquiring an additional 230 shares during the period. Harfst & Associates Inc. increased its holdings in shares of Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after acquiring an additional 260 shares during the period. Almanack Investment Partners LLC. acquired a new position in shares of Zoetis in the 2nd quarter valued at $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares during the period. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zoetis in the 2nd quarter valued at $140,000. 93.33% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Inc. (ZTS) remained flat at $$72.30 during trading hours on Friday. The company’s stock had a trading volume of 1,930,000 shares, compared to its average volume of 2,476,389. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis Inc. has a 52 week low of $48.54 and a 52 week high of $72.71. The firm has a market capitalization of $35,230.95, a price-to-earnings ratio of 33.17, a PEG ratio of 2.17 and a beta of 1.06.
The business also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were paid a dividend of $0.105 per share. The ex-dividend date of this dividend was Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.58%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.
A number of equities analysts have recently commented on the stock. Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a report on Monday, August 7th. BidaskClub cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. BMO Capital Markets boosted their price objective on shares of Zoetis from $65.00 to $70.00 and gave the company a “market perform” rating in a research note on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $68.24.
WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/02/mufg-americas-holdings-corp-sells-7149-shares-of-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.